Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization

Vaccine

Volumn 30, Issue 28, 2012, Pages 4276-4283

  Smith, Kenneth ^a   Crowe, Sherry R ^a,e   Garman, Lori ^a,b   Guthridge, Carla J ^a,c   Muther, Jennifer J ^a   McKee, Emily ^a   Zheng, Nai Ying ^d   Farris, A Darise ^a,b   Guthridge, Joel M ^a,b   Wilson, Patrick C ^d   James, Judith A ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c CAMERON UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e PharmAthene Inc   (United States)

Author keywords

Anthrax; Anthrax vaccine adsorbed; Human monoclonal antibodies; Passive immunotherapeutics; Protective antigen

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; CD19 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; FURIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY P1A06; MONOCLONAL ANTIBODY P1C03; MONOCLONAL ANTIBODY P3B03; MONOCLONAL ANTIBODY P5G03; MONOCLONAL ANTIBODY P6C01; MONOCLONAL ANTIBODY P6C04; MONOCLONAL ANTIBODY P6E02; MONOCLONAL ANTIBODY P6F01; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY SECRETING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OLIGOMERIZATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; SECRETORY CELL; VACCINATION;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; FEMALE; FURIN; HUMANS; IMMUNIZATION, PASSIVE; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED A; MIDDLE AGED; NEUTRALIZATION TESTS; PROTEIN MULTIMERIZATION; PROTEOLYSIS;

EID: 84861655341     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.002     Document Type: Article

References (41)

1. Mourez M. Anthrax toxins. Rev Physiol Biochem Pharmacol 2004, 152:135-164.
2. Jang J., Cho M., Chun J.H., Cho M.H., Park J., Oh H.B., et al. The poly-γ-d-glutamic acid capsule of Bacillus anthracis enhances lethal toxin activity. Infect Immun 2011, 79:3846-3854.
3. Young J.A., Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 2007, 76:243-265.
4. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature 1997, 385:833-838.
5. Cunningham K., Lacy D.B., Mogridge J., Collier R.J. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc Natl Acad Sci USA 2002, 99:7049-7053.
6. Goossens P.L. Animal models of human anthrax: the quest for the Holy Grail. Mol Aspects Med 2009, 30:467-480.
7. Marano N., Plikaytis B.D., Martin S.W., Rose C., Semenova V.A., Martin S.K., et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008, 300:1532-1543.
8. Crowe S.R., Ash L.L., Engler R.J., Ballard J.D., Harley J.B., Farris A.D., et al. Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J Infect Dis 2010, 202:251-260.
9. Chen Z., Moayeri M., Purcell R. Monoclonal antibody therapies against anthrax. Toxins 2011, 3:1004-1019.
10. Albrecht M.T., Li H., Williamson E.D., LeButt C.S., Flick-Smith H.C., Quinn C.P., et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 2007, 75:5425-5433.
11. Altboum Z., Gozes Y., Barnea A., Pass A., White M., Kobiler D. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun 2002, 70:6231-6241.
12. Kelly-Cirino C.D., Mantis N.J. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect Immun 2009, 77:4859-4867.
13. Little S.F., Leppla S.H., Burnett J.W., Friedlander A.M. Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem Biophys Res Commun 1994, 199:676-682.
14. Little S.F., Leppla S.H., Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 1988, 56:1807-1813.
15. Abboud N., De Jesus M., Nakouzi A., Cordero R., Pujato M., Fiser A., et al. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 1988, 56:1807-1813.
16. Gubbins M.J., Berry J.D., Corbett C.R., Mogridge J., Yuan X.Y., Schmidt L., et al. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol Med Microbiol 2006, 47:436-443.
17. Mohamed N., Clagett M., Li J., Jones S., Pincus S., D'Alia G., et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 2005, 73:795-802.
18. Rosenfeld R., Marcus H., Ben-Arie E., Lachmi B.E., Mechaly A., Reuveny S., et al. Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection. PLoS One 2009, 4:e6351.
19. Sawada-Hirai R., Jiang I., Wang F., Sun S.M., Nedellec R., Ruther P., et al. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines 2004, 2:5.
20. Wild M.A., Xin H., Maruyama T., Nolan M.J., Calveley P.M., Malone J.D., et al. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat Biotechnol 2003, 21:1305-1306.
21. Chen Z., Moayeri M., Zhou Y.H., Leppla S., Emerson S., Sebrell A., et al. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis 2006, 193:625-633.
22. Chen Z., Moayeri M., Crown D., Emerson S., Gorshkova I., Schuck P., et al. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun 2009, 77:3902-3908.
23. Reason D., Liberato J., Sun J., Keitel W., Zhou J. Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infect Immun 2009, 77:2030-2035.
24. Migone T.S., Subramanian G.M., Zhong J., Healey L.M., Corey A., Devalaraja M., et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009, 361(2):135-144.
25. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002, 99:11346-11350.
26. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
27. Smith K., Garman L., Wrammert J., Zheng N.Y., Capra J.D., Ahmed R., et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 2009, 4:372-384.
28. Mohamed N., Li J., Ferreira C.S., Little S.F., Friedlander A.M., Spitalny G.L., et al. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun 2004, 72:3276-3283.
29. Nguyen M.L., Crowe S.R., Kurella S., Teryzen S., Cao B., Ballard J.D., et al. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect Immun 2009, 77:162-169.
30. Wang F., Ruther P., Jiang I., Sawada-Hirai R., Sun S.M., Nedellec R., et al. Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly. Hum Antibodies 2004, 13:105-110.
31. Gordon V.M., Klimpel K.R., Arora N., Henderson M.A., Leppla S.H. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun 1995, 63:82-87.
32. Flick-Smith H.C., Walker N.J., Gibson P., Bullifent H., Hayward S., Miller J., et al. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 2002, 70:1653-1656.
33. Semenova V.A., Steward-Clark E., Stamey K.L., Taylor T.H., Schmidt D.S., Martin S.K., et al. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol 2004, 11:919-923.
34. Li H., Soroka S.D., Taylor T.H., Stamey K.L., Stinson K.W., Freeman A.E., et al. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods 2008, 333:89-106.
35. Park Y.S., Lee J.H., Hung C.F., Wu T.C., Kim T.W. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun 2008, 76:1952-1959.
36. McConnell M.J., Hanna P.C., Imperiale M.J. Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infect Immun 2006, 74:1009-1015.
37. Oscherwitz J., Yu F., Jacobs J.L., Liu T.H., Johnson P.R., Cease K.B. Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen. Infect Immun 2009, 77:3380-3388.
38. Oscherwitz J., Yu F., Cease K.B. A synthetic peptide vaccine directed against the 2β2-2β3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax. J Immunol 2010, 185:3661-3668.
39. Semenova V., Svoboda P., Pohl J., Quinn C.P. Peptide epitope mapping of anthrax protective antigen using sera of rhesus macaques that survived inhalation anthrax. The international conference on Bacillus anthracis, B. cereus & B. thuringiensis 2011, 150. Bacillus ACT, Bruges, Belgium, [abstract 67-Mo].
40. Taborda C.P., Rivera J., Zaragoza O., Casadevall A. More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol 2003, 170:3621-3630.
41. Peeling R., Maclean I.W., Brunham R.C. In vitro neutralization of Chlamydia trachomatis with monoclonal antibody to an epitope on the major outer membrane protein. Infect Immun 1984, 46:484-488.